Bristol Readies For Glucophage Generics: Adds 600 Reps, Refiles Vanlev
Executive Summary
Bristol-Myers Squibb will expand its sales force in 2002 despite an expected $1.7 bil. drop in Glucophage revenues due to the launch of metformin generics
You may also be interested in...
Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency
Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients
Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency
Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients
Merck Re-Sets Expectations For 2002: Zocor, Prilosec Are Possible Upsides
Merck's re-calibrated projections for 2002 provide some flexibility for the company if Zocor sales continue to be strong or the launch of generic versions of Prilosec are delayed